Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With

See also
Status	Clinical Trial	Phase
Completed	`NCT01200355` - Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome	Phase 4
Active, not recruiting	`NCT03755414` - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation	Phase 1
Recruiting	`NCT04904588` - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide	Phase 2
Active, not recruiting	`NCT04188678` - Resiliency in Older Adults Undergoing Bone Marrow Transplant	N/A
Completed	`NCT02543879` - Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies	Phase 1
Completed	`NCT01681537` - Lenalidomide Plus Chemotherapy for AML	Phase 1
Completed	`NCT01385423` - Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)	Phase 1
Terminated	`NCT01193400` - Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years	Phase 2
Completed	`NCT00995332` - Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine	Phase 1/Phase 2
Completed	`NCT00975975` - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer	Phase 2
Completed	`NCT00981240` - Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes	Phase 1
Completed	`NCT00726934` - The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients	N/A
Completed	`NCT00378534` - Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants	Phase 2
Completed	`NCT01031498` - Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting	Phase 2
Completed	`NCT00789256` - Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	N/A
Completed	`NCT00098033` - Investigation of Clofarabine in Acute Leukemias	Phase 2
Completed	`NCT01020539` - Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia	Phase 1
Not yet recruiting	`NCT04709458` - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis	Phase 1
Recruiting	`NCT04024241` - Medium Dose of Cytarabine and Mitoxantrone
Terminated	`NCT02203773` - Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)	Phase 1

NCT number	NCT01814826
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 1
Start date	April 10, 2013
Completion date	April 8, 2018

Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms